Paper Details

  1. Home
  2. Paper Details

Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing <i>BCR-ABL1</i> <sup>T315I</sup>-compound mutations.

Author: BergerDaniela, ByrgazovKonstantin, Degenfeld-SchonburgLina, EisenwortGregor, FilikYüksel, GleixnerKaroline V, LionThomas, MayerJiří, SadovnikIrina, SchewzikChristina, Schneeweiss-GleixnerMathias, SperrWolfgang R, StefanzlGabriele, ValentPeter

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study investigated the synergistic effects of asciminib and ponatinib, two tyrosine kinase inhibitors (TKIs), in patients with BCR-ABL1 T315I+ chronic myeloid leukemia (CML) who developed resistance to ponatinib. The combination of asciminib and ponatinib demonstrated synergistic growth-arrest and apoptosis-inducing effects in CML cell lines and patient-derived CML cells, including CML stem cells. The addition of hydroxyurea further enhanced these effects. The findings suggest that this combination of TKIs warrants further evaluation in clinical trials.
Paper Details　
Original Abstract of the Article :
Ponatinib is a tyrosine kinase inhibitor (TKI) directed against BCR-ABL1 which is successfully used in patients with <i>BCR-ABL1</i> <sup>T315I</sup>+ chronic myeloid leukemia (CML). However, <i>BCR-ABL1</i> compound mutations may develop during therapy in these patients and may lead to drug resista...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493398/

データ提供：米国国立医学図書館（NLM）

Combating Chronic Myeloid Leukemia: A New Approach

Cancer research is an ongoing quest to unravel the complexities of disease and develop new therapeutic approaches. This research focuses on the challenges of treating chronic myeloid leukemia (CML) patients who have developed resistance to conventional therapies. The study investigates the synergistic effects of asciminib and ponatinib, two novel drugs, in combination with hydroxyurea, in overcoming resistance to ponatinib in CML cells harboring specific mutations.

A New Desert Oasis for CML Treatment

The study offers a promising new strategy for treating CML patients who have developed resistance to ponatinib. The researchers found that combining asciminib, ponatinib, and hydroxyurea resulted in synergistic anti-leukemic effects, including apoptosis induction in CML stem cells. This combination therapy may represent a valuable option for patients with difficult-to-treat CML.

Hope for CML Patients: A Journey Through the Desert of Resistance

This research offers hope for CML patients who have exhausted conventional treatment options. The synergistic effects of the drug combination provide a new path for fighting this challenging disease and potentially improving patient outcomes.

Dr.Camel's Conclusion

This research underscores the power of collaboration in the fight against cancer. Like a caravan traversing the desert, researchers are pooling their expertise and resources to develop innovative therapies that can overcome resistance and offer new hope for patients with CML.

Date :
  1. Date Completed n.d.
  2. Date Revised 2021-10-22
Further Info :

Pubmed ID

34659899

DOI: Digital Object Identifier

PMC8493398

Related Literature

Article Analysis
・Effects of ponatinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.